Kiyatec Inc.

Neuro-oncologists must keep their patients' priorities in mind when determining their treatment plan. Whether it's their desire to attend the wedding of their child or complete a bucket list item, this is part of the overall conversation. With 3D Predict™, you have another tool to help patients plan for the future should the typical standard of care not work. We think this test should be a first step for all HGG patients. bit.ly/3DPredictHCP #Kiyatec #FunctionalPrecisionOncology #BrainCancer #HighGradeGlioma #CancerResearch #Oncologists #OncologyInnovation #TreatmentPlan #StandardOfCare #PatientSupport

Using standard-of-care TMZ + radiation to treat patients with HGG will typically only increase their survival rate by 2.5 months? But a recent study (go.nature.com/3XrcTpF) reveals that using the 3D Predict™ Glioma test prior to therapy, results in a significant increase in progression-free survival for predicted TMZ responders vs. nonresponders: ✅ 5.8 months for HGG patients ✅ 4.7 months for glioblastoma patients ✅ 4.7 months for those with MGMT unmethylated glioblastoma #3DPredict is crucial for tailoring effective treatment and it's changing the landscape of glioma care. By creating personalized treatment plans based on the results of this test, patients can have more time to achieve goals or make the most of the time they have left. 💡Let us help you and your patients make more informed decisions about their treatment: bit.ly/3DPredictGlioma #Kiyatec #FunctionalPrecisionOncology #Temozolomide #RadiationTherapy #BrainCancer #Glioblastoma #HighGradeGlioma #CancerResearch #StandardOfCare #SurvivalRate

Kiyatec's technology is here to help neuro-oncologists answer their patients' questions and assist them in making tough decisions as they battle an aggressive cancer. We all have the same goal: to give brain cancer patients the tools and support they need to determine their next steps. See how our technology works: bit.ly/3DPPlatform #Kiyatec #FunctionalPrecisionOncology #3DPredict #CancerResearch #OncologyInnovation #HealthcareInnovation #PatientCare #PatientSupport

Cancer treatment planning includes assessing the quality of patients' lives and their goals for the time they have left. This is where our 3D Predict™ test can help. In just 7-10 days, you'll be better equipped to have that conversation with your patients. Learn more about 3D Predict Glioma at: bit.ly/3DPredictGlioma #Kiyatec #FunctionalPrecisionOncology #3DPredict #Chemotherapy #InnovativeMedicine #TreatmentPlan #CancerCare #PatientCare

✅ A positive predictive value of 98%. ✅ Finding out in 10 days or less which drug killed a patient's cancer. ✅ Providing a personalized treatment plan that could give patients more time to accomplish their goals. Find out why so many neuro-oncologists are ordering 3D Predict™ for their patients with high-grade glioma. bit.ly/3DPredictHCP #Kiyatec #3DPredict #FunctionalPrecisionOncology #Kiyatec #CancerResearch #OncologyInnovation #HealthcareInnovation #PatientCare #CancerTherapy

This Breast Cancer Awareness Month, we’re standing strong with survivors, fighters, and all those impacted by breast cancer. At Kiyatec, we’re in it for the long haul, working toward innovations that will make a difference for every patient. While 3D Predict™ for breast cancer is still on the horizon, we’re committed to supporting every patient's journey — now and in the future.💪💖 #BreastCancerAwarenessMonth #SurvivorStrong #InItTogether #Kiyatec #3DPredict #CancerCare #FutureOfOncology

For three decades, the 5-year survival rate for HGG patients has been less than 10% when using standard of care treatment. But the #StuppProtocol, coupled with functional oncology, offers a more complete solution that can help patients make more confident decisions about their treatment. 🎯 With 3D Predict™, oncologists can improve clinical outcomes in HGG patients by aligning treatment strategies more closely to patient-specific responses. This can potentially improve both progression-free and overall survival. Read the study in Scientific Reports to see how functional precision oncology is transforming glioma care. ➡️ https://lnkd.in/eqGr_xhc #Kiyatec #3DPredict #FunctionalPrecisionOncology #OncologyInnovation #Oncologists #HGG #Glioma #ClinicalOutcomes #SurvivalRate #Chemotherapy #PatientCare #PatientSupport

🤞 The positive predictive value of the PD-L1 biomarker test is just 34%. 🌟 The positive predictive value of 3D Predict™? A game-changing 98%. When it comes to fighting cancer, certainty matters. 3D Predict™ helps provide patients and their doctors with a clear path forward — turning uncertainty into confidence. This difference could mean more time spent fighting effectively rather than wondering. 💪 #Kiyatec #3DPredict #FunctionalPrecisionOncology #CancerCare #OncologyInnovation #BetterOutcomes #PatientCare #PatientSupport

One of the key reasons oncologists trust 3D Predict™? It quickly identifies which chemotherapy will work for their patients—and which won’t. By removing the guesswork, our test spares patients the frustration and harsh side effects of ineffective treatments. Curious about how it works? Check out our case studies and resources to learn more. 👉 bit.ly/KiyatecResources #3DPredict #OncologyInnovation #PrecisionMedicine #CancerCare #PatientCare #Oncology #CancerTreatment #PersonalizedMedicine #HealthcareInnovation #Kiyatec #ChemoTreatment

CEO Soundbites: "We want cancer patients to get the most appropriate treatment and avoid the complications that come with treatment that isn't going to work. By providing this information, we allow the patient and their clinical team to make more appropriate and more confident decisions in the drugs that they're going to take." – Eric Perreault See what we do at: www.Kiyatec.com #3DPredict #CEOPerspective #CancerCare #OncologyInnovation #PrecisionMedicine #PatientCare #HealthcareLeadership #CancerTreatment #CancerResearch #PersonalizedMedicine